Skip to main content
OpenTrials
Completed

NCT Number: NCT05221983

COVID-19 and Vitamin D: Length of Hospital Stay and Mortality

The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition. In this context, can the protective properties of vitamin D play an important role in this pandemic? brought with it the thought. In this study, it was aimed to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Pandemic Avitaminosis COVID-19 Coronaviridae Infections Coronavirus Infections Deficiency Diseases Infections Lung Diseases Malnutrition Nidovirales Infections Nutrition Disorders Nutritional and Metabolic Diseases Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases Vitamin D Deficiency

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Republic of Turkey Ministry of Health Ankara City Hospitals Neurology-Orthopedics Hospital

Ankara, 06800, Turkey (Türkiye)

About this study

This research was conducted to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease. For this, the approval of the Ministry of Health and then the ethics committee was obtained. For this reason, patients with positive PCR tests and hospitalized patients with vitamin D levels in their biochemistry were included in the study.

The data of the patients were obtained from the medical records. Information such as age, gender, comorbidities, length of hospital stay, vitamin D level were included in the study. According to the statistical analyzes obtained from these data, it has been shown that vitamin D level has no effect on mortality and hospital stay in COVID-19 disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID-19 PCR (Polymerase Chain Reaction) test positive
  • Vitamin D level in biochemical parameters
  • Adult patients hospitalized for COVID-19

Exclusion criteria

-Patients using drugs that may affect vitamin D absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents

Treatment and study plan

Primary outcomes

  1. Level of Vitamin D

    Time frame: 1 month later

    Vitamin D levels of patients with a diagnosis of COVID-10. These results were categorized at the level of deficiency/insufficiency/normal.

  2. Relationship between vitamin D level and mortality

    Time frame: 1 month later

    Relationship between survival and death by categorized vitamin D level.

  3. Relationship between vitamin D level and hospital stay

    Time frame: 1 month later

    Length of hospital stay by categorized vitamin D level.

Secondary outcomes

  1. Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality

    Time frame: 1 month later.

    Evaluation of the impact of comorbidities on survival during COVID-19 disease.

Sponsors and collaborators

Lead sponsor

Yuksek Ihtisas University

Other

Collaborators

  • Ankara City Hospital Bilkent

Registry information

Official study title

Vitamin D Level: Reflections of a Public Health Issue in the COVID-19 Pandemic. Does it Affect Mortality and Length of Hospital Stay?

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Feb 3, 2022
Registry last updated
Feb 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.